Inflazyme Pharmaceuticals (T.IZP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sean Janzen who wrote (1386)	1/23/2000 6:58:00 PM
From: Sean Janzen	Read Replies (1) of 1501

A follow up to that last thought. The phrasing from the interview with Ian McBeath suggest IZP management believes they are close to finding a new pathway that could lead to a whole new way of treating inflammation. >>One thing that is especially exciting is that we are busily working, along with our partner Aventis, to identify the mechanism of action, at the cellular level, of the IPL576 series of molecules. We believe that it is possible that these molecules may be exerting their effects through a previously undiscovered cellular target. If this proves to be so, then we may have discovered a new pathway that could lead into the development of a whole new way of treating inflammation. This could then position Inflazyme at the forefront of anti-inflammatory companies. << One of the sessions at the conference Inflazyme management will attend next month in New York is: Inflammation: A new Pathway to Stop Disease in its Tracks It looks like a match. I hope I'm not reading too much into this.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next